NCT01830725|CompletedDMC
Purine Metabolism Enzyme SNP to Uric Acid Production
Relationship of Purine Metabolism Enzyme Single-Nucleotide Polymorphisms to Uric Acid Production and Response to Xanthine Oxidase Inhibitors
Loading search results
Relationship of Purine Metabolism Enzyme Single-Nucleotide Polymorphisms to Uric Acid Production and Response to Xanthine Oxidase Inhibitors
Sponsor study identifier
observational
100
1 country
1
Study Start
December 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2016
Actual (reported)Study Completion
June 2016
Actual (reported)Determine whether a relationship exists between polymorphisms of the genes XDH, HPRT1, and PRPS1 and gout, hyperuricemia, or the dose of xanthine oxidase (XO) inhibitors to reach a goal serum uric acid of less than 6 mg/dL. This study is observational in nature as no dose adjustment of XO inhibitors will be made by study investigators.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2016
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2012
Date type not reportedThis date has not been verified as actual or estimated.
April 5, 2013
Actual (reported)April 12, 2013
Actual (reported)June 2016
Actual (reported)June 2016
Actual (reported)Relationship of SNPs to gout, hyperuricemia, and dose of xanthine oxidase inhibitor needed to reach goal serum uric acid level of < 6 mg/dL.
This study will test the relationship of 2107A\>G XO to the dose of allopurinol needed to achieve a treatment goal of less than 6 mg/dL. It will also test whether or not SNPs affecting the gene for hypoxanthine phosphoribosyltransferase 1 (HPRT1) are related to gout, hyperuricemia, or the dose of XO inhibitor needed to reach a goal of 6 mg/dL. Relationships will be determined using typical non-parametric or parametric tests depending on the skew and skedasticity. \- Determine the relationship of several SNPs in genes encoding HPRT1 and one XO SNP (2107A\>G) to the dose of xanthine oxidase inhibitor needed to achieve a goal treatment uric acid level of less than 6 mg/dL.
2 years
Determine frequency of SNPs tested
2 years
Determine relationship of XO SNP 2107A>G and several HPRT1 SNPs to hyperuricemia/gout.
2 years
Subjects with a diagnosis of hyperuricemia (defined as a uric acid of \> 7.2 mg/dl) and/or gout.
Approximate age and gender matched controls without hyperuricemia or gout
Patients for either the gout/hyperuricemia group or the control group will be recruited at the time of their evaluation in either the Internal Medicine (IM) Clinic or IM Specialties Clinic.
Keesler Medical Center
Keesler Air Force Base, Mississippi, 39564, United States
DNA will be banked for future studies as allowed by patient consent
Matthew B Carroll, MD
Keesler Medical Center
100 participants (actual enrollment reported by the registry).
First Submitted
April 5, 2013
First Posted
April 12, 2013
Study Start
December 2012
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
June 2016
Actual (reported)Study Completion
June 2016
Actual (reported)Last Updated
August 30, 2016
Record last verified: 2016-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: